Therapeutic Drug Monitoring and Individualized Dosing

Therapeutic drug monitoring (TDM) is the practice of measuring the concentration of a drug in a patient's blood or other fluid and using that measurement to individualize the dose. It is most useful for medicines whose effect tracks concentration more reliably than dose, and whose therapeutic and toxic ranges lie close together.

Definition

Therapeutic drug monitoring is the measurement of drug concentrations in biological fluids, interpreted against pharmacokinetic principles and a defined target exposure, in order to individualize dosing for a given patient.

Scope

This entry covers the rationale for measuring drug concentrations, the pharmacokinetic concepts that make a measurement interpretable, and the characteristics that make a drug a candidate for monitoring. It treats TDM as a methodological topic within pharmacotherapy optimization and does not provide target ranges, sampling instructions, or dosing advice.

Core questions

• Why does the same dose produce different concentrations and effects in different patients?
• Which drug characteristics make concentration measurement worthwhile?
• How is a measured concentration interpreted in relation to dosing and timing?
• How does monitoring contribute to balancing efficacy against toxicity?

Key concepts

• Therapeutic range
• Narrow therapeutic index
• Pharmacokinetic variability
• Clearance and half-life
• Steady state and trough sampling
• Concentration-response relationship
• Dose individualization

Key theories

Concentration-response relationship

For many drugs the pharmacological effect, and the risk of toxicity, relate more consistently to the concentration at the site of action than to the administered dose; when a measurable concentration in an accessible fluid tracks that effect, it can guide individualized dosing.

Mechanisms

TDM exploits the fact that drug response often tracks concentration more closely than dose, while the concentration achieved by a fixed dose varies between patients because clearance, volume of distribution, and other parameters differ (Wilkinson, 2005; Rowland & Tozer, 2011). By measuring concentration, typically once a steady state has been reached and at a defined time relative to dosing, the regimen can be adjusted toward a target exposure associated with benefit while staying below concentrations associated with toxicity. Monitoring is most valuable when the therapeutic range is narrow, when concentration predicts effect better than dose does, and when an assay and a meaningful target exist (Rowland & Tozer, 2011).

Clinical relevance

TDM is a core activity in clinical pharmacy and clinical pharmacology, supporting individualized care and the avoidance of concentration-dependent harm (Edwards & Aronson, 2000). This entry describes the principles by which monitoring is reasoned about and is reference and educational material; it does not state target concentrations or provide dosing, sampling, or treatment instructions for any drug or patient.

Evidence & guidelines

The interpretation of concentrations rests on clinical pharmacokinetic principles (Rowland & Tozer, 2011; Wilkinson, 2005). Drug- and assay-specific target ranges, sampling times, and adjustment algorithms are defined in professional guidance, laboratory standards, and drug labeling, which lie outside this reference entry.

History

As clinical pharmacokinetics matured through the second half of the twentieth century, it became possible to relate drug effect and toxicity to measurable concentrations rather than to dose alone (Wilkinson, 2005). Reliable assays for drugs with narrow therapeutic ranges made routine concentration measurement feasible, and clinical pharmacokinetics texts codified the concepts of clearance, steady state, and target exposure that underpin interpretation (Rowland & Tozer, 2011).

Key figures

• Malcolm Rowland
• Thomas Tozer
• Grant Wilkinson

Seminal works

• rowland-tozer-2011
• wilkinson-2005

Frequently asked questions

Which drugs are candidates for therapeutic drug monitoring?

Drugs whose effect or toxicity tracks concentration better than dose, that have a narrow margin between therapeutic and toxic concentrations, that show wide variability between patients, and for which a reliable assay and a meaningful target exposure exist.

Does therapeutic drug monitoring replace clinical judgement?

No. A concentration is interpreted alongside the patient's clinical response, the timing of the sample relative to dosing, and pharmacokinetic principles; it informs rather than replaces clinical assessment.